8 unknown, 5 recruiting, 4 completed, 2 not yet recruiting. 15 Phase 2, 3 Phase 1, 2 Not applicable, 1 Phase 3.
Follow this condition Literature Review of MSS trials Research Report on MSS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NCT + PD1 + Ketogenic Diet and/or Vitamin C for LARC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 100 | 2026-09-01 | 2026-08-14 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases short-course radiotherapy, CAPEOX/XELOX, Serplulimab - Colorectal Carcinoma, Oligometastases | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 51 | 2025-04-22 | 2026-03-25 |
| SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 2 | Completed | Sixth Affiliated Hospital, Sun Yat-sen University | 49 | 2025-04-02 | 2026-08-04 |
| Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Colorectal Cancer Ivosidenib (AK112) - CRC, MSS | Phase 2 | Not yet recruiting | Fudan University | 36 | 2024-11-01 | 2024-09-19 |
| Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody - Metastatic Colorectal Cancer, MSS | Phase 2 | Unknown | Zhangfa Song | 36 | 2024-06-01 | 2024-05-16 |
| ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC irinotecan, cetuximab, envafolimab - RAS Mutation, Metastatic Colorectal Cancer | Phase 2 | Recruiting | Beijing Hospital | 60 | 2024-03-01 | 2026-07-28 |
| Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment HAIC+targeted therapy+PD-1 inhibitor - Liver Metastasis Colon Cancer, ctDNA Genotype | Not applicable | Completed | Peking University | 47 | 2024-01-23 | 2026-07-28 |
| Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer Rego+Tori+Cele - Colorectal Cancer, Liver Metastases | Phase 2 | Unknown | Sun Yat-sen University | 44 | 2023-12-19 | 2024-02-06 |
| Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer Toripalimab, short-term radiotherapy, Oxaliplatin - Locally Advanced, High-Risk | Not applicable | Unknown | Nanfang Hospital, Southern Medical University | 53 | 2023-07-01 | 2023-07-05 |
| RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC RP2, RP3, atezolizumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Terminated | Replimune, Inc. | 5 | 2023-06-29 | 2026-02-02 |
| XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer Cadonilimab, Oxaliplatin, Capecitabine - Rectal Cancer, MSS | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 92 | 2023-03-29 | 2023-04-18 |
| Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Serplulimab, Capecitabine, Oxaliplatin - pMMR, MSS | Phase 2 | Recruiting | Zhejiang University | 50 | 2023-02-22 | 2026-03-05 |
| Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer Atezolizumab, Therasphere, XELOX - Metastatic Colorectal Cancer, pMMR | Phase 2 | Unknown | Federation Francophone de Cancerologie Digestive | 52 | 2020-10-07 | 2023-08-18 |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer Bevacizumab, Tripleitriumab - Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 50 | 2020-09-20 | 2020-09-17 |
| Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma. TKI ± anti-PD-1 antibody - MSS, pMMR | Phase 2 | Unknown | China Medical University, China | 53 | 2020-07-24 | 2021-10-05 |
| Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer ATP128, BI 754091, VSV-GP128 - Colorectal Cancer, MSS | Phase 1 | Active not recruiting | Amal Therapeutics | 96 | 2019-07-22 | 2025-01-29 |
| Regorafenib and PD-1 Antibody in Combination With Radiotherapy for pMMR/MSS Metastatic Colorectal Cancer Regorafenib and PD-1 antibody in Combination with Radiotherapy, Radiation therapy - Colorectal Cancer Metastatic, MSS | Phase 2 | Unknown | Sun Yat-sen University | 28 | 2019-07-19 | 2023-03-23 |
| Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC Pembrolizumab, Maraviroc - Metastatic Colorectal Cancer, MSS | Phase 1 | Completed | University Hospital Heidelberg | 20 | 2018-04-01 | 2022-06-07 |
Showing 20 of 21. Sign in to see all of them.
Colorectal Neoplasms (9) · Rectal Neoplasms (7) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Stomach Neoplasms (1) · Vaccinia (1)
Neoplasms (17) · Digestive System Diseases (16) · Digestive System Neoplasms (16) · Gastrointestinal Diseases (16) · Gastrointestinal Neoplasms (16) · Neoplasms by Site (16) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Rectal Diseases (15) · Colonic Diseases (9) · Colorectal Neoplasms (6) · DNA Virus Infections (1) · Esophageal Diseases (1) · Head and Neck Neoplasms (1) · Infections (1)
Bevacizumab (6) · Surgical Procedures, Operative (4) · spartalizumab (4) · Capecitabine (3) · Cetuximab (3) · Oxaliplatin (3) · XELOX (2) · atezolizumab (2) · Ascorbic Acid (1) · Celecoxib (1) · Diet, Ketogenic (1) · Immune Checkpoint Inhibitors (1) · Ipilimumab (1) · Irinotecan (1) · Maraviroc (1)
Sixth Affiliated Hospital, Sun Yat-sen University (3) · Sun Yat-sen University (2) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Amal Therapeutics (1) · Beijing Hospital (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · China Medical University, China (1) · Federation Francophone de Cancerologie Digestive (1) · First Affiliated Hospital of Zhejiang University (1) · Fudan University (1) · Nanfang Hospital, Southern Medical University (1) · Peking University (1) · Pfizer (1) · Replimune, Inc. (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (15) · United States (4) · Belgium (2) · Germany (2) · France (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Dehua Wu, MD (1) · Gary Vanasse, MD (1) · Guohui Wan, PhD. (1) · Jingdong Zhang (1) · Juan Huang, PhD. (1) · Jun Huang, PhD (1) · Jun Huang, PhD. (1) · Patrick Wagner, MD (1) · Scott Kopetz (1) · Xiaodong Wang, M.D. (1) · Yanhong Deng, M.D. (1) · Yanhong Deng, docter (1) · Ying Yuan, M.D. (1)
PMID 23177514, PMID 25970050, PMID 25981818, PMID 29946728, PMID 35379611, PMID 35427833, PMID 38314087, PMID 38600471
2017 (1), 2019 (1)